Atos SE (EPA:ATO)
55.36
-0.78 (-1.39%)
At close: Jan 30, 2026
Atos SE Revenue
Atos SE had revenue of 4.02B EUR in the half year ending June 30, 2025, a decrease of -27.11%. This brings the company's revenue in the last twelve months to 8.63B, down -14.88% year-over-year. In the year 2024, Atos SE had annual revenue of 9.58B, down -10.44%.
Revenue (ttm)
8.63B
Revenue Growth
-14.88%
P/S Ratio
0.12
Revenue / Employee
124.04K
Employees
69,597
Market Cap
1.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.58B | -1.12B | -10.44% |
| Dec 31, 2023 | 10.69B | -577.00M | -5.12% |
| Dec 31, 2022 | 11.27B | 431.00M | 3.98% |
| Dec 31, 2021 | 10.84B | -342.00M | -3.06% |
| Dec 31, 2020 | 11.18B | -407.00M | -3.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Capgemini SE | 22.07B |
| Sopra Steria Group | 5.67B |
| Alten | 4.12B |
| Solutions 30 SE | 946.00M |
| Wavestone | 943.94M |
| Neurones | 832.18M |
| Aubay Société Anonyme | 537.22M |
| Keyrus | 346.70M |
Atos SE News
- 11 days ago - Atos Anticipates Significant Revenue Decline Amid Ongoing Restructuring Efforts - GuruFocus
- 11 days ago - France's Atos flags steep revenue decline for 2025 - Reuters
- 12 days ago - Atos and Graia unite to break language barriers in the workplace with real-time voice translation - GlobeNewsWire
- 12 days ago - After-Hours Gainers: ATOS, IBRX, FEMY, FHTX, DARE, TBPH - Nasdaq
- 15 days ago - ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
- 23 days ago - Atos Announces a Strategic Partnership with the World DanceSport Federation to Drive its Technological Evolution - GlobeNewsWire
- 27 days ago - Avenga Appoints Clay Van Doren as Chief Executive Officer - Benzinga
- 5 weeks ago - Atos Signs Binding Deal To Sell South American Business To Brazil's Semantix - Nasdaq